Abingworth

Abingworth has invested in over 185 life science and healthcare companies since its founding, supporting the development of dozens of new medicines. Its clinical co-development strategy has contributed to more than thirty FDA approvals through partnerships with major pharma and biotech firms.

Notable supported drugs include Pfizer’s Besponsa, Eisai’s Lenvima, and Apellis Pharmaceuticals’ Empaveli.

The firm provides both capital and operational support—including clinical/regulatory teams—to help advance late-stage programs toward approval.

Recent funds have focused on pivotal-stage biotherapeutics with high probability of near-term commercialization.

Portfolio breadth includes early-stage startups as well as late-stage clinical assets across multiple modalities.

Over the last decade alone, more than thirty FDA approvals have been achieved by portfolio companies.

Recent investments include Ascend Cell and Gene Therapies, Entact Bio, Wugen, AdvanCell Therapeutics among others.